What Biobank does

BIOBank (legal entity SAS BIOBank) is a French specialty medical device company founded in 1999 and headquartered in Lieusaint, France, that manufactures and distributes human bone allografts. Its core technology is the proprietary Supercrit® process, which applies supercritical CO2 delipidation combined with chemical oxidation of residual proteins to bone tissue harvested from living donors; the process preserves the native mineral-collagen structure and biomechanical properties of bone while delivering validated viral inactivation exceeding the SAL 10^-6 regulatory threshold across a broad virus panel (validated independently by the Pasteur Institute and Texcell). The company sells a comprehensive orthopaedic/spine portfolio — whole and half femoral heads, wedges, cancellous blocks, dowels, granules, and powder-in-syringe formats — and a dental/maxillofacial portfolio including cancellous and cortico-cancellous powders, cortical plates, and patient-specific customized grafts produced from CT/Cone-Beam imaging with 3D modeling and printing.

BIOBank distributes its products exclusively against nominative medical prescription to orthopaedic, spine, dental and maxillofacial surgeons in hospitals, clinics and private practices via a direct sales motion with dedicated phone lines per segment. Revenue is generated through one-time purchases of graft units at undisclosed list pricing; there is no subscription, recurring, or licensing revenue stream. The company holds ANSM authorization (since 2003), was the first tissue bank globally to obtain ISO 13485 certification for bone allografts, and is FDA registered, supporting both domestic dominance (>50% French market share) and stated international expansion ambitions. Following the May 2024 sale of a majority stake to IK Partners' IK Small Cap III Fund (with management reinvesting), BIOBank is positioned to scale market share, expand internationally, and develop new products.

Name

Biobank

Legal name

SAS BIOBank

Website

https://biobank.fr

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

BIOBank is a French manufacturer and distributor of viro-inactivated human bone allografts, processed via its proprietary Supercrit® supercritical CO2 technology, serving orthopaedic, spine, and dental/maxillofacial surgeons on nominative medical prescription; it holds over 50% French market share, is the first tissue bank ISO 13485-certified for bone allografts, and is FDA registered.

Ownership category

akta.pro rank

Product category

Bone Allografts / Tissue Banking

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Dental Implant Surgery & Bone Grafting (HLABAEAB)

Keywords

• Bone allografts
• Tissue banking
• Orthopedic surgical products
• Dental bone grafts
• Viro-inactivated grafts

Headquarters

HQ city

Lieusaint

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Bone Allograft Products: BIOBank manufactures and distributes a range of processed bone allograft products (femoral head grafts, wedges, blocks, granules, powders, custom grafts) to orthopaedic, spine, and oral/maxillofacial surgeons. Products are sold as one-time purchases against nominative medical prescriptions, with no subscription or recurring revenue model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BIOBank manufactures and distributes viro-inactivated human bone allografts processed through its patented Supercrit® supercritical CO2 process for orthopaedic, spine and oral/maxillofacial surgeons in France. The product range covers whole and half femoral heads, wedges, cancellous blocks, dowels, granules, powders (in vial and syringe presentations), cortical plates, cortico-cancellous plates and CT/Cone-Beam-customised grafts. All products are delivered sterile in double airtight packaging with a five-year shelf life and sold exclusively on nominative medical prescription.

Product overview

BIOBank is a French manufacturer and distributor of bone allografts for orthopedic, spine, dental, and cranio-maxillofacial surgery. The company offers a comprehensive portfolio of products derived from human femoral heads harvested exclusively from living donors in France. All products are processed using the proprietary Supercrit® process, which uses supercritical CO2 for delipidation combined with chemical oxidation for viral inactivation. The orthopedic/spine range includes whole and half femoral heads, bone wedges, cancellous blocks, bone dowels, granules, and powder in various presentations. The dental range includes cancellous and cortico-cancellous bone powders, cortical plates, and the innovative Customized Bone Graft prepared from CT-scan/Cone-Beam imaging. The company holds ISO 13485 certification and FDA registration, commanding over 50% market share in France.

Differentiator

Problem solved

Functional benefit

Brands

• Supercrit®: Proprietary bone tissue treatment process based on supercritical CO2 delipidation combined with chemical oxidation for viral inactivation of bone allografts.

Products and services

• Whole Femoral Head Allograft Complete femoral head bone allograft for filling segmental bone loss and structural grafts in arthroplasty revisions, tumour curettage, fracture osteosynthesis, osteotomy and spinal arthrodesis procedures. Sold to orthopaedic and spine surgeons on nominative medical prescription.
• Half Femoral Head Allograft Half femoral head allograft for filling segmental bone loss and structural grafts in orthopaedic and spinal procedures. Sold to orthopaedic and spine surgeons on nominative medical prescription.
• Bone Wedge Bone wedges available in 6mm to 14mm sizes for structural bone grafting and spinal arthrodesis procedures.
• Cancellous Bone Block Cancellous bone blocks in various dimensions used to fill bone loss and provide structural grafts in orthopaedic procedures.
• Cancellous Bone Dowels Cancellous bone dowels in 9mm to 14mm diameters primarily used for ligamentoplasty reconstruction procedures.
• Cancellous Bone Granules Cancellous bone granules supplied in vials or syringes at 7cc, 18cc or 25cc volumes for filling bone defects in orthopaedic and spinal procedures.
• Cancellous Bone Powder in Syringe Cancellous bone powder supplied in a specifically designed syringe with luer-lock connector for semi-closed rehydration with sterile sodium chloride solution, enabling direct aseptic dispensing into the grafting site. Available in 0.5cc, 1cc and 2cc volumes.
• Cancellous Bone Powder (Dental) Cancellous bone powder in vial presentation available in S (0.5mm) and L (1mm) granulometries for dental and maxillofacial procedures including peri-implant filling, sinus floor elevation and extraction socket filling.
• Cortico-Cancellous Bone Powder (Dental) Cortico-cancellous bone powder for dental applications including peri-implant filling, sinus floor elevation and extraction socket filling.
• Cortical Bone Plates Cortical bone plates available in 12x10mm and 18x10mm sizes for guided bone regeneration as an alternative to autologous grafts before dental implant placement.
• Cortico-Cancellous Plates Cortico-cancellous plates in 15x10x4mm and 22x12x4mm sizes for dental and maxillofacial reconstruction procedures.
• Cancellous Bone Block (Dental) Cancellous bone block in 20x10x10mm dimensions used for autologous harvest site regeneration in dental procedures.
• Customized Bone Graft (Greffon sur mesure) Custom-designed bone graft prepared from CT-scan or Cone-Beam imaging using 3D modelling and printing, available in cortico-cancellous or cancellous types, pre-machined to match patient anatomy. Enables pre-operative planning on a 3D silicone model, reducing surgical time and improving graft-host bone congruence, and processed through the same Supercrit® workflow as standard BIOBank grafts.

Quantifiable outcome

• 95.3% successful cervical fusion and 90.5% lumbar fusion rates using Supercrit® allografts, with >80% of patients reporting good to excellent outcomes per Odom's scores
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Pasteur Institute / TexcellcoreStrategic or Co-development PartnerBIOBank partnered with the Pasteur Institute (studies in 1995 and 2003) and its spin-off Texcell (study in 2022) to scientifically validate the viral inactivation efficacy of the Supercrit® process. These studies demonstrated that the process exceeds the Security Assurance Level of 10^-6 across multiple virus categories including HIV, HCV, HBV, Parvovirus, and SARS-CoV-2.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Zimmer Biomet: Global orthopedic reconstruction leader with bone graft and biologics offerings across joint reconstruction, spine, and dental. Broad incumbent competing in the same surgical indications where Biobank's allografts are used.
• Stryker: Global orthopedics and medical devices incumbent offering bone graft substitutes (including synthetic and biologics portfolios) and orthopedic surgical products. Competes with Biobank through breadth of orthopedic offerings and scale advantages.
• Medtronic: Global medical device leader with the Infuse Bone Graft (rhBMP-2) product, a dominant bone graft substitute in spinal fusion. Represents the largest competitive threat to Biobank's spine business through an entirely synthetic alternative with global commercial reach.

Direct peers

• AlloSource: US non-profit tissue bank manufacturing allografts for orthopedic, spine, and dental reconstruction. Direct peer in the bone allograft category with overlapping customer base of surgeons and hospitals.
• LifeNet Health: One of the largest global tissue banks providing allograft bone and other musculoskeletal grafts for orthopedic, spine, and dental procedures. Direct competitor to Biobank in the bone allograft category with overlapping surgeon customers and similar regulatory positioning.
• MTF Biologics: US-based non-profit tissue bank and one of the world's largest providers of bone, cartilage, and soft tissue allografts. Competes directly with Biobank in bone allografts and serves many of the same orthopedic and spine surgery indications.
• Xtant Medical: US-listed developer and manufacturer of regenerative medicine products including bone allografts for spine and orthopedic surgery. Direct competitor in the bone allograft space with comparable hospital-channel GTM.
• restor3d (formerly RTI Surgical): US-based company with a meaningful bone allograft and spine portfolio alongside 3D-printed implant capabilities. Direct competitor in bone allografts and increasingly in customized implants—an area where Biobank's "Greffon sur mesure" competes.
• Geistlich Pharma: Swiss-headquartered leader in dental bone regeneration with the Bio-Oss and Bio-Gide lines used in sinus lifts, peri-implant grafting, and guided bone regeneration. Direct competitor in Biobank's dental/maxillofacial bone graft segment, particularly in European markets.

Emerging players

• botiss biomaterials: European (German) dental bone and soft tissue regeneration specialist offering allograft, xenograft, and synthetic bone graft substitutes. Competes with Biobank's dental range and shares a European sales footprint focused on implantology.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biobank